This medical device company develops vascular implants designed to prevent or promote blood clot formation, tailored to individual patient needs. Their technology aims to reduce or eliminate the need for dual antiplatelet therapy post-procedure, thereby mitigating bleeding and thrombotic risks for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Patients receiving vascular implants face a significant risk of thrombosis, often requiring dual antiplatelet therapy (DAPT) to prevent blood clot formation. DAPT carries its own risks, including major bleeding events, creating a clinical challenge of balancing thrombosis and hemorrhage prevention. Current market solutions may have limitations in addressing these dual risks effectively.
Solution
Piezolabs is developing vascular implants that utilize a piezoelectric material to generate a surface charge upon implantation, modulating blood interaction at the implant site. The electric potential created by the pulsatile movement of vessels de-aggregates platelets and blood components, preventing thrombosis. This technology aims to reduce or eliminate the need for DAPT post-procedure, thereby mitigating bleeding risks associated with antiplatelet medications. The implants can be tailored to either prevent or promote clot formation based on individual patient needs, offering a versatile solution for enhanced vascular health.
Target Audience
The primary target audience includes interventional neurologists, peripheral vascular surgeons, and cardiologists who perform vascular implant procedures and seek to minimize the risks associated with DAPT.
Features
- Surface modification with novel piezoelectric material that generates an electric potential upon deformation.
- Electric potential controls platelet aggregation, with negative potential reversing aggregation.
- Local anti-platelet action that extends beyond the implant surface.
- Potential to shorten or eliminate the need for DAPT.
- Reduced bleeding and thrombosis risks compared to traditional solutions.
- Versatile application for both anti-thrombotic and thrombotic surface modification.